> top > docs > PubMed:26505133 > annotations

PubMed:26505133 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-142 Sentence denotes Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
TextSentencer_T2 143-359 Sentence denotes Mutations of Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), accounting for approximately 30% of patients with acute myeloid leukemia (AML), results in poor therapeutic efficacy and short survival.
TextSentencer_T3 360-473 Sentence denotes Sorafenib, an oral multikinase inhibitor, can inhibit FLT3 and improve clinical outcome of FLT3 mutated leukemia.
TextSentencer_T4 474-658 Sentence denotes Our current studies have shown that, the antidiabetic drug metformin also exerts anti-leukemic effect by activating p-AMPK and synergistically sensitizes FLT3 mutated AML to sorafenib.
TextSentencer_T5 659-840 Sentence denotes Both agents suppress cell proliferation in a dose-dependent manner and induce apoptosis via cell cycle arrest, but does not obviously modulate autophagy marker, light chain 3 (LC3).
TextSentencer_T6 841-1130 Sentence denotes Mechanistically, in the presence of metformin, the anticancer potential of sorafenib, accompanying with increased LC3 levels, is found to be synergistically enhanced with the remarkably reduced protein expression of the mTOR/p70S6K/4EBP1 pathway, while not appreciably altering cell cycle.
TextSentencer_T7 1131-1281 Sentence denotes Overall, these results show metformin in aid of sorafenib may represent a promising and attractive strategy for the treatment of FLT3-ITD mutated AML.
T1 0-142 Sentence denotes Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
T2 143-359 Sentence denotes Mutations of Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), accounting for approximately 30% of patients with acute myeloid leukemia (AML), results in poor therapeutic efficacy and short survival.
T3 360-473 Sentence denotes Sorafenib, an oral multikinase inhibitor, can inhibit FLT3 and improve clinical outcome of FLT3 mutated leukemia.
T4 474-658 Sentence denotes Our current studies have shown that, the antidiabetic drug metformin also exerts anti-leukemic effect by activating p-AMPK and synergistically sensitizes FLT3 mutated AML to sorafenib.
T5 659-840 Sentence denotes Both agents suppress cell proliferation in a dose-dependent manner and induce apoptosis via cell cycle arrest, but does not obviously modulate autophagy marker, light chain 3 (LC3).
T6 841-1130 Sentence denotes Mechanistically, in the presence of metformin, the anticancer potential of sorafenib, accompanying with increased LC3 levels, is found to be synergistically enhanced with the remarkably reduced protein expression of the mTOR/p70S6K/4EBP1 pathway, while not appreciably altering cell cycle.
T7 1131-1281 Sentence denotes Overall, these results show metformin in aid of sorafenib may represent a promising and attractive strategy for the treatment of FLT3-ITD mutated AML.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
26505133-0#37#41#gene2322 37-41 gene2322 denotes FLT3
26505133-0#55#77#diseaseC0023467 55-77 diseaseC0023467 denotes acute myeloid leukemia
26505133-2#54#58#gene2322 414-418 gene2322 denotes FLT3
26505133-2#91#95#gene2322 451-455 gene2322 denotes FLT3
26505133-2#104#112#diseaseC0023418 464-472 diseaseC0023418 denotes leukemia
26505133-3#118#122#gene5562 592-596 gene5562 denotes AMPK
26505133-3#118#122#gene5563 592-596 gene5563 denotes AMPK
26505133-3#118#122#gene5564 592-596 gene5564 denotes AMPK
26505133-3#167#170#diseaseC0023467 641-644 diseaseC0023467 denotes AML
37#41#gene232255#77#diseaseC0023467 26505133-0#37#41#gene2322 26505133-0#55#77#diseaseC0023467 associated_with FLT3,acute myeloid leukemia
54#58#gene2322104#112#diseaseC0023418 26505133-2#54#58#gene2322 26505133-2#104#112#diseaseC0023418 associated_with FLT3,leukemia
91#95#gene2322104#112#diseaseC0023418 26505133-2#91#95#gene2322 26505133-2#104#112#diseaseC0023418 associated_with FLT3,leukemia
118#122#gene5562167#170#diseaseC0023467 26505133-3#118#122#gene5562 26505133-3#167#170#diseaseC0023467 associated_with AMPK,AML
118#122#gene5563167#170#diseaseC0023467 26505133-3#118#122#gene5563 26505133-3#167#170#diseaseC0023467 associated_with AMPK,AML
118#122#gene5564167#170#diseaseC0023467 26505133-3#118#122#gene5564 26505133-3#167#170#diseaseC0023467 associated_with AMPK,AML

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T2184 592-596 gene:5562 denotes AMPK
T2185 641-644 disease:C0023467 denotes AML
R1 T2184 T2185 associated_with AMPK,AML
R2 T2184 T2185 associated_with AMPK,AML
R3 T2184 T2185 associated_with AMPK,AML